Home > Market > Market Stats >  Glenmark Life Sciences

Glenmark Life Sciences

Sector: Biotechnology & Drugs
Powered by
381.85 +1.10 (0.29%)
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y

Price Range

Today’s Low 380.05
Today’s High 387.95
52 Week Low 375.6
52 Week High 679.0

Key Metrics

  • Market Cap (In Cr) 4672.57
  • Beta -
  • Div. Yield (%) 5.51
  • P/B 2.27
  • TTM P/E 12.21
  • Peg Ratio 2.17
  • Sector P/E 25.43
  • D/E -
  • Open Price 387.95
  • Prev Close 380.75
View All Metrics on Mint Genie

Analysis

Price Analysis
  • 1 Week
    -0.69%
  • 3 Months
    -15.13%
  • 6 Month
    -25.35%
  • YTD
    -39.57%
  • 1 Year
    -43.31%
Risk Meter
  • 23% Low risk
  • 23% Moderate risk
  • 23% Balanced Risk
  • 23% High risk
  • 23% Extreme risk
Recos
4 Analysts
  • Strong Sell
  • Sell
  • Hold
  • Buy
  • Strong Buy
Analysts' Views
  • Ratings
  • Current
  • Strong Sell
  • 0
  • Sell
  • 0
  • Hold
  • 0
  • Buy
  • 2
  • Strong Buy
  • 2

Financials

  • INCOME
  • BALANCE SHEET
  • Cashflow
  • Period
  • 2022
  • Total Revenue
  • 2123.21
  • Selling/ General/ Admin Expenses Total
  • 463.52
  • Depreciation/ Amortization
  • 37.88
  • Other Operating Expenses Total
  • -0.32
  • Total Operating Expense
  • 1543.97
  • Operating Income
  • 579.24
  • Net Income Before Taxes
  • 564.92
  • Net Income
  • 418.72
  • Diluted Normalized EPS
  • 35.67
  • Period
  • 2021
  • Total Revenue
  • 1885.17
  • Selling/ General/ Admin Expenses Total
  • 384.55
  • Depreciation/ Amortization
  • 33.39
  • Other Operating Expenses Total
  • -0.38
  • Total Operating Expense
  • 1323.06
  • Operating Income
  • 562.1
  • Net Income Before Taxes
  • 470.94
  • Net Income
  • 351.58
  • Diluted Normalized EPS
  • 28.73
  • Period
  • 2020
  • Total Revenue
  • 1537.31
  • Selling/ General/ Admin Expenses Total
  • 373.66
  • Depreciation/ Amortization
  • 29.37
  • Other Operating Expenses Total
  • -0.4
  • Total Operating Expense
  • 1093.1
  • Operating Income
  • 444.22
  • Net Income Before Taxes
  • 421.07
  • Net Income
  • 313.1
  • Diluted Normalized EPS
  • 25.63
  • Period
  • 2019
  • Total Revenue
  • 886.42
  • Selling/ General/ Admin Expenses Total
  • 279.06
  • Depreciation/ Amortization
  • 6.95
  • Other Operating Expenses Total
  • 12.28
  • Total Operating Expense
  • 650.58
  • Operating Income
  • 235.84
  • Net Income Before Taxes
  • 228.3
  • Net Income
  • 195.59
  • Diluted Normalized EPS
  • 16.01
View detailed financials on Mint Genie

Forecast

Income Sheet (In Cr) Net Income Vs Revenue
Returns Metrics (In Cr) ROA Vs ROE

Technical

Moving Average SMA
  • 5 Day382.83
  • 10 Day394.78
  • 20 Day413.96
  • 50 Day435.73
  • 100 Day441.27
  • 300 Day487.02

Peers

  • Price
  • Ratio
  • Name
  • Latest Price
  • Change
  • % Change
  • 52W High
  • 52W Low
  • Mkt. Cap
  • FDC
  • 284
  • 7.9
  • 2.86
  • 366
  • 229.15
  • 4679.49
  • Hikal
  • 334.85
  • 9.8
  • 3.01
  • 595
  • 215.65
  • 4104.68

Corporate Actions

  • Board Meeting
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
  • Meeting Date
  • Purpose
  • 04-Aug-22
  • Quarterly Results
  • 20-Apr-22
  • Audited Results & Final Dividend
  • 08-Feb-22
  • Quarterly Results
  • 10-Nov-21
  • Quarterly Results

Company Profile

ABOUT Glenmark Life Sciences

  • Industry Biotechnology & Drugs
  • ISIN INE03Q201024
  • BSE Code 543322
  • NSE Code GLS

Glenmark Life Sciences Limited is an India-based company that is primarily engaged in the business of development, manufacture and marketing of active pharmaceutical ingredients (API). The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.

MANAGEMENT

  • Glenn Saldanha Non-Executive Chairman of the Board
  • Yasir Rawjee Chief Executive Officer, Managing Director, Executive Director
  • Tushar Mistry Chief Financial Officer, Senior Vice President
  • Sumantra Mitra Senior Vice President - Human Resources, Executive Director
  • Rudalf Corriea Company Secretary, Compliance Officer
  • Mathew George Vice President, Head of Regulatory Affairs
  • Vinod Naik Group Vice President, Head of Technical Operations
  • Palle Acharyulu Group Vice President - Research & Development
  • Navin Agrawal Head - Corporate Quality, API

Company Summary

GLENMARK LIFE SCIENCES SUMMARY

Glenmark Life Sciences is trading 0.29% upper at Rs 381.85 as compared to its last closing price. Glenmark Life Sciences has been trading in the price range of 387.95 & 380.05. Glenmark Life Sciences has given -39.57% in this year & -0.69% in the last 5 days.

 

Glenmark Life Sciences has TTM P/E ratio 12.21 as compared to the sector P/E of 25.43. There are 4 analysts who have initiated coverage on Glenmark Life Sciences. There are 2 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.

 

The company posted a net profit of 108.73 Crores in its last quarter.

 

Listed peers of Glenmark Life Sciences include Jubilant Pharmova (2.51%), FDC (2.86%), Glenmark Life Sciences (0.29%) etc.

FAQs about Glenmark Life Sciences

Glenmark Life Sciences is trading at 381.85 as on 4 Oct, 2022 3:29:59 PM. This is 0.29% upper as compared to its previous closing price of 380.75
The market capitalization of Glenmark Life Sciences is 4672.57 Cr as on 4 Oct, 2022 3:29:59 PM.
The average broker rating on Glenmark Life Sciences is Strong Buy. The breakup of analyst rating is given below -
  • 0 analysts have given a strong sell rating
  • 0 analysts have given a sell rating
  • 0 analysts have given a hold rating
  • 2 analysts have given a buy rating
  • 2 analysts have given a strong buy rating
The 52 wk high for Glenmark Life Sciences is 679.0 whereas the 52 wk low is 375.6
Glenmark Life Sciences can be analyzed on the following key metrics -
  • TTM P/E: 12.21
  • Sector P/E: 25.43
  • Dividend Yield: 5.51%
  • D/E ratio: -
Glenmark Life Sciences reported a net profit of 418.72 Cr in 2022.

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout